On an Internet chat room popular with breast cancer survivors, one thread — called “Where’s My Remote?” — turns the mental fog known as chemo brain into a stand-up comedy act.
Interactive Health Communication for longer, better lives.
In this issue of Blood, Kristinsson and colleagues report an increased risk of venous and arterial thrombosis in MGUS and multiple myeloma in a population-based study including 18 627 patients with multiple myeloma, 5326 patients with MGUS, and 70 991 controls.1
Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.
But a Loyola University Health System study has found the drug aprepitant can dramatically reduce both nausea and vomiting when combined with other anti-nausea drugs.
The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group
It may someday be possible to take the antioxidant N-acetylcysteine (NAC) before ultraviolet exposure, to prevent oxidative stress in nevi and thereby reduce the risk of melanoma, researchers say in the December 1st issue of Clinical Cancer Research.
They base this speculation on the results of a study in which 19 patients at high risk for skin cancer agreed to have nevi removed immediately before and three hours after they took a single dose (1,200 mg) of NAC.
Hepatoxicity caused by chemotherapy can be successfully treated with milk thistle (MT), according to a study of children with acute lymphoblastic leukemia (ALL) published online December 14 in Cancer.
The new anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) could replace the older product, warfarin, say researchers presenting new data from a large clinical trial in patients with acute venous thromboembolism (the RECOVER study). The results show that dabigatran is as effective and as safe as, if not safer than, the older agent, but it also offers the advantage of a fixed dose and no need for blood monitoring, as opposed to the regular monitoring and dose adjustment needed with warfarin.
The overall incidence of bisphosphonate-associated osteonecrosis of the jaw is relatively low. Preventative measures such as maintaining good oral hygiene are likely the best management strategy for the disorder.
Venous thromboembolism (VTE) is a common complication in cancer patients and a significant cause of morbidity and mortality. In fact, thrombosis is the second most common cause of death among hospitalized and ambulatory cancer patients. However, many cancer patients still are not receiving VTE prophylaxis and treatment, despite the demonstrated effectiveness of anticoagulant therapies and practice-guideline recommendations, notes a review published online June 26 in the Annals of Oncology,
For >50 years, warfarin anticoagulation has been a standard treatment for prophylaxis and treatment of VTE. For treatment of VTE, it has typically been given after initial therapy with unfractionated heparin (UFH) or, more recently, a low-molecular weight heparin (LMWH).[42]
If you have ever slept on an arm and awakened with a “dead” hand, or sat too long with your legs crossed and had your foot fall asleep, you have some inkling of what many people with peripheral neuropathy experience day in and day out, often with no relief in sight.
MANILA, Philippines--Each and every one of us has experienced some form of blood clotting at some point in our lives.
We usually observe this whenever we cut or bruise ourselves—the streaming blood would eventually “harden,” forming clumps that in time, stops the bleeding (although it depends on how big or how deep the wound is).
This is part of the body’s natural mechanism to seal the damaged blood vessel and to prevent more blood from leaking out.
Millions of people suffer peripheral pain and other troubling sensations accompanying diseases as varied as diabetes, AIDS, shingles and arthritis. Cancer patients also often suffer these so-called peripheral neuropathies because of their therapies.
Peripheral neuropathies include disorders of a nerve or nerves outside the brain and spinal cord; they can precipitate tingling, numbness, weakness, burning pain and other unwelcome sensations.
To think that today’s irritation, an itch, rash, sore throat, cough, swelling,
pain here, pain there, bump, or a lump could someday result in cancer, heart
attack, allergy, arthritis, diabetes, obesity, osteoporosis, depression, or
Alzheimer, though hard to imagine, can be a reality tomorrow. Extensive
research within the last half a century has made it clear that human body is
made up of approximately 25,000 genes. It is the choreography between
these genes and their interaction with the environment has been found to
Below is yesterday's blog entry from Margaret's Corner. First and foremost, Margaret highlights yet another benefit of curcumin supplementation. A second and perhaps more important issue that Margaret highlights is that cachexia effects about 50% of cancer survivors.
"Cachexia is a syndrome that unfortunately affects about 50% of cancer patients and, in general, people with chronic diseases such as AIDS or COPD."
The huge meta-analysis of individual patient data that confirmed an increased mortality in cancer patients treated with erythropoiesis-stimulating agents (ESAs) has been published in the May 2 issue of the Lancet.
The researchers analyzed individual data for 13,933 cancer patients participating in 53 trials, and found that ESAs increased the relative risk for mortality by 17%. When they considered only cancer patients who were undergoing chemotherapy (10,441 patients in 38 trials), they found that ESAs increased the relative risk by 10%.
On an Internet chat room popular with breast cancer survivors, one thread — called “Where’s My Remote?” — turns the mental fog known as chemo brain into a stand-up comedy act.
|